MCID: HYP086
MIFTS: 68

Hypothyroidism

Categories: Endocrine diseases, Fetal diseases, Immune diseases, Mental diseases, Metabolic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypothyroidism

MalaCards integrated aliases for Hypothyroidism:

Name: Hypothyroidism 11 75 28 53 5 41 43 14 16 71 75 33
Thyroid Diseases 53 41 71
Thyroid Disease 16 75
Thyroid Insufficiency 11
Dysfunction Thyroid 53
Thyroid Dysfunction 71
Thyroid Deficiency 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1459
ICD9CM 34 244.9
MeSH 43 D007037
NCIt 49 C26800
SNOMED-CT 68 267465007
UMLS 71 C0020676 C0040128 C0348024

Summaries for Hypothyroidism

MedlinePlus: 41 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It is one of your endocrine glands, which make hormones. Thyroid hormones control the rate of many activities in your body. These include how fast you burn calories and how fast your heart beats. All of these activities are your body's metabolism. Thyroid problems include: Goiter - enlargement of the thyroid gland Hyperthyroidism - when your thyroid gland makes more thyroid hormones than your body needs Hypothyroidism - when your thyroid gland does not make enough thyroid hormones Thyroid cancer Thyroid nodules - lumps in the thyroid gland Thyroiditis - swelling of the thyroid To diagnose thyroid diseases, doctors use a medical history, physical exam, and thyroid tests. They sometimes also use a biopsy. Treatment depends on the problem, but may include medicines, radioiodine therapy, or thyroid surgery. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary: Hypothyroidism, also known as thyroid diseases, is related to congenital hypothyroidism and hypothyroidism, congenital, nongoitrous, 1. An important gene associated with Hypothyroidism is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid stimulating hormone (TSH) signaling pathway and Thyroid hormones production and peripheral downstream signaling effects. The drugs Nitroprusside and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include thyroid, heart and lymph node, and related phenotypes are Resistant to vaccinia virus (VACV-A4L) infection and homeostasis/metabolism

Disease Ontology: 11 A thyroid gland disease which involves an underproduction of thyroid hormone.

Wikipedia 75 Hypothyroidism: Hypothyroidism (also called underactive thyroid, low thyroid or hypothyreosis) is a disorder of the... more...

Thyroid disease: Thyroid disease is a medical condition that affects the function of the thyroid gland. The thyroid gland... more...

Related Diseases for Hypothyroidism

Diseases in the Hypothyroidism family:

Congenital Hypothyroidism Central Congenital Hypothyroidism
Hypothyroidism Due to Iodide Transport Defect Rare Adult Hypothyroidism
Transient Congenital Hypothyroidism Rare Hypothyroidism
Primary Congenital Hypothyroidism Hypothyroidism Due to Deficient Transcription Factors Involved in Pituitary Development or Function
Congenital Hypothyroidism Due to Maternal Intake of Antithyroid Drugs Transient Congenital Hypothyroidism Due to Maternal Factor
Transient Congenital Hypothyroidism Due to Neonatal Factor Congenital Hypothyroidism Due to Transplacental Passage of Tsh-Binding Inhibitory Antibodies
Congenital Hypothyroidism Due to Developmental Anomaly

Diseases related to Hypothyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2045)
# Related Disease Score Top Affiliating Genes
1 congenital hypothyroidism 33.7 TSHR TSHB TRHR TRH TPO TG
2 hypothyroidism, congenital, nongoitrous, 1 33.6 TSHR TSHB TG PAX8 IYD GLIS3
3 hypothyroidism, congenital, nongoitrous, 2 33.6 TSHR TG SLC26A4 PAX8 NKX2-1
4 hypothyroidism, central, with testicular enlargement 33.2 TSHB TRHR TRH
5 diabetes mellitus, neonatal, with congenital hypothyroidism 33.1 SLC5A5 IYD GLIS3
6 hypothyroidism, congenital, nongoitrous, 4 33.1 TSHB TPO TG
7 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 33.1 TSHR SLC26A4 PAX8 NKX2-1 IYD
8 pendred syndrome 33.0 TPO TG SLC5A5 SLC26A4 PAX8 IYD
9 hyperthyroidism 32.9 TSHR TRHR TRH TPO TG SERPINA7
10 postsurgical hypothyroidism 32.8 TSHR TPO TG
11 hashimoto thyroiditis 32.8 TSHR TPO TG SLC26A4 SERPINA7 RET
12 thyroid dyshormonogenesis 1 32.8 SLC5A5 PAX8
13 myxedema 32.7 TSHR TSHB TPO TG SERPINA7
14 iodine hypothyroidism 32.6 TSHR TPO TG
15 thyroid dyshormonogenesis 2a 32.6 TSHR TPO TG RET PAX8 NKX2-1
16 thyroid dyshormonogenesis 4 32.6 IYD DIO3
17 familial thyroid dyshormonogenesis 32.5 TPO TG SLC5A5 SERPINA7 IYD DIO3
18 graves disease 1 32.5 TSHR TRH TPO TG SLC5A5 SERPINA7
19 athyreosis 32.4 TSHR SLC26A4 PAX8 NKX2-5 NKX2-1
20 thyroid ectopia 32.2 PAX8 NKX2-5
21 subacute thyroiditis 32.2 TSHR TPO TG SERPINA7
22 thyroid crisis 32.1 TSHR TPO TG SERPINA7
23 goiter 32.1 TSHR TRH TPO TG SLC5A5 SLC26A4
24 thyroiditis 32.0 TSHR TSHB TPO TG SERPINA7 RET
25 graves' disease 32.0 TSHR TPO TG SERPINA7 PAX8
26 nontoxic goiter 31.4 TSHR TPO TG SERPINA7
27 adenoma 31.3 TSHR TSHB TRH TG RET
28 endemic goiter 31.2 TSHR TSHB TRH TPO TG SLC5A5
29 euthyroid sick syndrome 31.2 TRH TG SERPINA7 DIO3
30 exophthalmos 31.2 TSHR TPO TG
31 turner syndrome 31.1 TPO TG SERPINA7
32 nodular goiter 31.1 TSHR TPO TG SLC5A5 RET
33 multinodular goiter 31.0 TSHR TRH TPO TG SLC5A5 SLC26A4
34 thyroid hormone resistance, generalized, autosomal dominant 31.0 TSHR TSHB TRH TG SERPINA7
35 differentiated thyroid carcinoma 31.0 RET PAX8 NKX2-1
36 celiac disease 1 30.9 TPO TG STAT1 IFNA1
37 graves ophthalmopathy 30.9 TSHR TG
38 plummer's disease 30.9 TSHR TPO TG SLC5A5 SERPINA7
39 goiter, multinodular 1, with or without sertoli-leydig cell tumors 30.9 TPO TG
40 hyperthyroxinemia 30.8 TSHR TPO SERPINA7
41 hypothalamic disease 30.7 TSHB TRH
42 neonatal thyrotoxicosis 30.7 TSHR TG DIO3
43 papillary carcinoma 30.6 TSHR TPO TG RET PAX8 NKX2-1
44 dyshormonogenic goiter 30.6 TG SLC5A5 SLC26A4 IYD
45 thyroid hormone resistance, selective pituitary 30.6 TSHB TRH TG SERPINA7
46 autoimmune polyendocrine syndrome 30.6 TG STAT1 IFNA1
47 thyroid cancer, nonmedullary, 2 30.6 TSHR TG PAX8
48 suppurative thyroiditis 30.5 TSHR TPO TG SLC5A5
49 hypotropia 30.5 TSHR TPO
50 papillary thyroid microcarcinoma 30.4 TG NKX2-1

Comorbidity relations with Hypothyroidism via Phenotypic Disease Network (PDN): (show top 50) (show all 153)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Allergic Rhinitis Alzheimer Disease, Familial, 1
Anxiety Aortic Valve Disease 1
Atypical Depressive Disorder Autonomic Nervous System Disease
Basilar Artery Insufficiency Benign Essential Hypertension
Bipolar Disorder Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Celiac Disease 1
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Disease
Chronic Pulmonary Heart Disease Communicating Hydrocephalus
Congenital Hypothyroidism Conjunctivitis
Conn's Syndrome Conversion Disorder
Cystitis Decubitus Ulcer
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dermatomycosis
Diabetes Insipidus Diabetic Polyneuropathy
Dyshormonogenic Goiter Dyskinesia of Esophagus
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development Esophagitis
Exophthalmos Familial Atrial Fibrillation
Female Breast Cancer Female Stress Incontinence
Femoral Vein Thrombophlebitis First-Degree Atrioventricular Block
Gastroesophageal Reflux Generalized Anxiety Disorder

Graphical network of the top 20 diseases related to Hypothyroidism:



Diseases related to Hypothyroidism

Symptoms & Phenotypes for Hypothyroidism

GenomeRNAi Phenotypes related to Hypothyroidism according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Resistant to vaccinia virus (VACV-A4L) infection GR00351-A-1 9.17 GLIS3 GNB1 IFNA1 RET SERPINA7 SLC26A4

MGI Mouse Phenotypes related to Hypothyroidism:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 CHD7 DIO3 GLIS3 NKX2-1 NKX2-5 PAX8
2 growth/size/body region MP:0005378 10.34 CHD7 DIO3 GLIS3 GNB1 NKX2-1 NKX2-5
3 nervous system MP:0003631 10.29 CHD7 GNB1 NKX2-1 NKX2-5 PAX8 RET
4 endocrine/exocrine gland MP:0005379 10.25 CHD7 GLIS3 NKX2-1 NKX2-5 PAX8 RET
5 behavior/neurological MP:0005386 10.07 CHD7 GNB1 NKX2-1 PAX8 RET SLC26A4
6 cellular MP:0005384 10.06 CHD7 DIO3 GLIS3 GNB1 NKX2-1 NKX2-5
7 limbs/digits/tail MP:0005371 10.04 CHD7 PAX8 RET STAT1 TG TPO
8 hearing/vestibular/ear MP:0005377 10 CHD7 PAX8 SLC26A4 SLC5A5 TG TPO
9 digestive/alimentary MP:0005381 9.97 CHD7 NKX2-1 NKX2-5 RET SLC26A4 STAT1
10 respiratory system MP:0005388 9.7 CHD7 GNB1 IFNA1 NKX2-1 NKX2-5 RET
11 reproductive system MP:0005389 9.65 CHD7 DIO3 NKX2-1 PAX8 RET SLC26A4
12 skeleton MP:0005390 9.36 CHD7 GNB1 NKX2-1 PAX8 SLC26A4 SLC5A5

Drugs & Therapeutics for Hypothyroidism

Drugs for Hypothyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 364, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Iron Approved Phase 4 7439-89-6 29936
4
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
5
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
6
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
9
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
10
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Codeine Approved, Illicit Phase 4 76-57-3, 6854-40-6 5284371 5362471
14
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
18
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
19
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
22
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
23
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
24
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181
25
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
26
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
27
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 4 133585-56-5, 556-02-5, 60-18-4 1153 6057
28
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 4 461-06-3
29
Cobalamin Experimental Phase 4 13408-78-1 6857388
30 Carboxymethylcellulose Sodium Phase 4
31 Vasodilator Agents Phase 4
32 Antacids Phase 4
33 Anti-Ulcer Agents Phase 4
34 Proton Pump Inhibitors Phase 4
35 Vitamin B12 Phase 4
36 Vitamin B 12 Phase 4
37 Antipyretics Phase 4
38 Antitussive Agents Phase 4
39 Technetium Tc 99m Medronate Phase 4
40 Methylene diphosphonate Phase 4
41 Diphosphonates Phase 4
42 Anesthetics Phase 4
43 Anesthetics, Local Phase 4
44 Narcotics Phase 4
45 Analgesics, Opioid Phase 4
46 Sodium Channel Blockers Phase 4
47 Diuretics, Potassium Sparing Phase 4
48 Anticonvulsants Phase 4
49 Tocolytic Agents Phase 4
50 calcium channel blockers Phase 4
51
Insulin Phase 4
52 Insulin, Globin Zinc Phase 4
53 Respiratory System Agents Phase 4
54
protease inhibitors Phase 4
55 HIV Protease Inhibitors Phase 4
56 Anti-Asthmatic Agents Phase 4
57 Betamethasone-17,21-dipropionate Phase 4
58
Betamethasone Valerate Phase 4 2152-44-5
59
Betamethasone sodium phosphate Phase 4
60
Betamethasone benzoate Phase 4
61
Triamcinolone hexacetonide Phase 4
62
Triamcinolone diacetate Phase 4
63
Triamcinolone Acetonide Phase 4 6436
64 Hypoglycemic Agents Phase 4
65 Incretins Phase 4
66
Sitagliptin Phosphate Phase 4 654671-77-9
67 Dipeptidyl-Peptidase IV Inhibitors Phase 4
68 Selenium Supplement Phase 4
69 Technetium Tc 99m Sestamibi Phase 4
70 Adjuvants, Immunologic Phase 4
71 Proxymetacaine Phase 4
72 Viscosupplements Phase 4
73
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
74
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
75
Cholecystokinin Approved, Investigational Phase 3 9011-97-6 16129670
76
Ursodeoxycholic acid Approved, Investigational Phase 3 128-13-2 31401
77
Simvastatin Approved Phase 3 79902-63-9 54454
78
Diclofenac Approved, Vet_approved Phase 3 15307-86-5, 15307-79-6 3033
79
Pralsetinib Approved, Investigational Phase 3 2097132-94-8 129073603
80
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
81
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
82 Bile Acids and Salts Phase 3
83 Lipid Regulating Agents Phase 3
84 Anticholesteremic Agents Phase 3
85 Hypolipidemic Agents Phase 3
86 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
87 Endothelial Growth Factors Phase 3
88 Antibodies, Monoclonal Phase 3
89 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
90
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
91
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
92
Methimazole Approved Phase 2 60-56-0 1349907
93
Oxytetracycline Approved, Investigational, Vet_approved Phase 1, Phase 2 79-57-2 54715139 54675779
94
Ketorolac Approved Phase 2 74103-06-3, 66635-83-4 3826
95
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
96
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
97
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
98
Salicylic acid Approved, Investigational, Vet_approved Phase 2 69-72-7 338
99
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
100
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
101
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
102
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
103
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
104
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
105
Pasireotide Approved Phase 2 396091-73-9 56841596 9941444
106
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
107
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
108
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
109
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
110
Turmeric Approved, Experimental, Investigational Phase 1, Phase 2
111
Licorice Approved Phase 1, Phase 2
112
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
113
Aflibercept Approved Phase 2 862111-32-8 124490314
114
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605 16129706
115
Denosumab Approved Phase 2 615258-40-7
116
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
117
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
118
Trastuzumab Approved, Investigational Phase 2 180288-69-1
119
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
120
Pertuzumab Approved Phase 2 380610-27-5
121
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
122
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
123
Adenosine Approved, Investigational Phase 2 58-61-7 60961
124
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
125
Osimertinib Approved Phase 2 1421373-65-0 71496458
126
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
127
Afatinib Approved Phase 2 439081-18-2, 850140-72-6 53445376 10184653
128
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
129
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
130
Trametinib Approved Phase 2 871700-17-3 11707110
131
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
132
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
133
Nivolumab Approved Phase 2 946414-94-4
134
Ipilimumab Approved Phase 2 477202-00-9
135
Vemurafenib Approved Phase 2 918504-65-1 42611257
136
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
137
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
138
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
139
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
140
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
141
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
142
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
143
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 155817456
144
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
145
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
146
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
147
Levodopa Approved Phase 2 59-92-7, 63-84-3 6047
148
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
149
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 2942 5351166
150
Lanreotide Approved Phase 2 108736-35-2 71349 6918011
151
Lithium carbonate Approved Phase 2 554-13-2
152
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
153
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
154
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
155
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
156
Aspartic acid Approved, Nutraceutical Phase 2 56-84-8 5960
157
Asparagine Approved, Investigational, Nutraceutical Phase 2 70-47-3 6267
158
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
159
Imetelstat Investigational Phase 2 868169-64-6
160
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
161
Irofulven Investigational Phase 2 158440-71-2 3844471 148189
162
Tipifarnib Investigational Phase 2 192185-72-1 159324
163
Tremelimumab Investigational Phase 2 745013-59-6
164
MK-1775 Investigational Phase 2 955365-80-7 24856436
165
GSK-2636771 Investigational Phase 2 1372540-25-4 56949517
166
Spartalizumab Investigational Phase 2 1935694-88-4
167
Rivoceranib Investigational Phase 2 811803-05-1 11315474
168
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2 91976570
169
Efatutazone Investigational Phase 1, Phase 2 223132-37-4 9832447
170 Antidiarrheals Phase 1, Phase 2
171
Calcium Aluminosilicate Phase 1, Phase 2
172 Caraway Phase 1, Phase 2
173 N-Methylaspartate Phase 2
174 Brewer's Yeast Phase 2
175 Liver Extracts Phase 2
176 Thyrotropin-Releasing Hormone Phase 2
177 Fluorodeoxyglucose F18 Phase 2
178 Motesanib diphosphate Phase 2
179 Vaccines Phase 2
180 Folic Acid Antagonists Phase 2
181 Deoxyglucose Phase 2
182
Histamine phosphate Phase 1, Phase 2 51-74-1 134614
183 polysaccharide-K Phase 2
184 Histone Deacetylase Inhibitors Phase 2
185 Hawthorn Phase 1, Phase 2
186 Turmeric extract Phase 1, Phase 2
187 Chinese Yam Phase 1, Phase 2
188 Chinese Salvia Phase 1, Phase 2
189 Chinese Rhubarb Phase 1, Phase 2
190 Astragalus Phase 1, Phase 2
191 Skullcap Phase 1, Phase 2
192 Chelating Agents Phase 2
193 Antimalarials Phase 2
194 Antiprotozoal Agents Phase 2
195 Antiparasitic Agents Phase 2
196 Antibodies, Bispecific Phase 2
197 Immunoglobulins, Intravenous Phase 2
198 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid Phase 2
199 Interleukin-2 Phase 2
200 Immunoglobulin G Phase 2
201
Ado-Trastuzumab Emtansine Phase 2
202
Maytansine Phase 2
203 Trastuzumab biosimilar HLX02 Phase 2
204 Piperazine citrate Phase 2
205 DMP 777 Phase 2 157341-41-8
206 Immunoconjugates Phase 2
207 Immune Checkpoint Inhibitors Phase 2
208 Epinephryl borate Phase 2
209 Vasoconstrictor Agents Phase 2
210 Mydriatics Phase 2
211 Bronchodilator Agents Phase 2
212 Sympathomimetics Phase 2
213 Adrenergic beta-Agonists Phase 2
214 Antifungal Agents Phase 2
215 Antimetabolites Phase 2
216
Calcitonin Phase 2
217 Katacalcin Phase 2 16172926
218 Cyclooxygenase Inhibitors Phase 2
219 Anti-Inflammatory Agents, Non-Steroidal Phase 2
220 Analgesics, Non-Narcotic Phase 2
221 Analgesics Phase 2
222 Anti-Bacterial Agents Phase 2
223 Antibiotics, Antitubercular Phase 2
224 Antineoplastic Agents, Immunological Phase 2
225 Liposomal doxorubicin Phase 2
226 Angiogenesis Inhibitors Phase 2
227 Psychotropic Drugs Phase 2
228
Imatinib Mesylate Phase 1, Phase 2 220127-57-1
229
Gallium 68 PSMA-11 Phase 2 91800164
230 Dihydroxyphenylalanine Phase 2
231 Antiparkinson Agents Phase 2
232 Dopamine Agents Phase 2
233 Antidepressive Agents Phase 2
234 Lubricant Eye Drops Phase 2
235 Cyclooxygenase 2 Inhibitors Phase 2
236 Proteasome Inhibitors Phase 1, Phase 2
237
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
238
Hydrocodone Approved, Illicit, Investigational Phase 1 125-29-1 5284569
239
Oxycodone Approved, Illicit, Investigational Phase 1 76-42-6 5284603
240
Ibuprofen Approved Phase 1 15687-27-1 3672
241
Rosiglitazone Approved, Investigational Phase 1 122320-73-4, 155141-29-0 77999
242
Ethanol Approved Phase 1 64-17-5 702
243
Mechlorethamine Approved, Investigational Phase 1 51-75-2 4033
244
Etoposide Approved Phase 1 33419-42-0 36462
245
Picropodophyllin Approved, Investigational Phase 1 518-28-5, 477-47-4 10607 72435
246
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
247
Cetuximab Approved Phase 1 205923-56-4
248
Lapatinib Approved, Investigational Phase 1 231277-92-2, 388082-78-8 208908
249
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 1 63-91-2, 673-06-3 6140 71567
250
Polygeline Experimental Phase 1 66455-30-9
251 Iron Supplement Phase 1
252 Anti-Infective Agents, Local Phase 1
253 Radiopharmaceuticals Phase 1
254 Interleukin-12 Phase 1
255 Blood Substitutes Phase 1
256 Plasma Substitutes Phase 1
257 Gastrins Phase 1
258 Dermatologic Agents Phase 1
259
Etoposide phosphate Phase 1 16760419
260 Keratolytic Agents Phase 1
261
Pitavastatin Approved 147511-69-1 5282452
262
Pancrelipase Approved, Investigational 53608-75-6 8519
263
Methylthioninium Approved, Experimental, Investigational 61-73-4, 7060-82-4 6099
264
Sodium citrate Approved, Investigational 68-04-2 23431961
265
Carbimazole Approved, Investigational 22232-54-8 31072
266
Epitestosterone Approved, Experimental, Investigational 481-30-1, 58-22-0 5408 10204 6013
267
Calcium carbonate Approved, Investigational 471-34-1
268
Mecobalamin Approved, Investigational 13422-55-4
269
Neostigmine Approved, Vet_approved 59-99-4 4456 5824
270
Glycopyrronium Approved, Investigational, Vet_approved 596-51-0, 740028-90-4 3494
271
Valsartan Approved, Investigational Early Phase 1 137862-53-4 60846
272
Rocuronium Approved 119302-91-9, 143558-00-3 441290
273
Remifentanil Approved 132875-61-7 60815
274
Bexarotene Approved, Investigational Early Phase 1 153559-49-0 82146
275
Gefitinib Approved, Investigational 184475-35-2 123631
276
Silver sulfadiazine Approved, Vet_approved 22199-08-2 441244
277
Povidone-iodine Approved 25655-41-8
278
Povidone K30 Approved, Experimental 9003-39-8 6917 131751496
279
Metronidazole Approved 443-48-1, 69198-10-3 4173
280
Cefazolin Approved 25953-19-9 33255
281
Piperacillin Approved 66258-76-2 43672
282
Lovastatin Approved, Investigational 75330-75-5 53232
283
Vildagliptin Approved, Investigational 274901-16-5 6918537
284
Alendronic acid Approved 121268-17-5, 66376-36-1 2088
285
Formaldehyde Approved, Vet_approved 50-00-0 712
286
Bupivacaine Approved, Investigational 2180-92-9, 38396-39-3 2474
287
Acetylsalicylic acid Approved, Vet_approved 50-78-2 2244
288
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943
289
Dexmedetomidine Approved, Experimental, Vet_approved 86347-14-0, 113775-47-6 68602 5311068
290
Tamsulosin Approved, Investigational 106133-20-4 129211
291
Silicon Approved, Investigational 7440-21-3 4082203
292
Cisatracurium Approved 96946-41-7 62887
293
Durvalumab Approved, Investigational Early Phase 1 1428935-60-7
294
Liraglutide Approved 204656-20-2 44147092 16134956
295
Glucagon Approved 16941-32-5 16133228 16186314
296
Exenatide Approved, Investigational 141758-74-9 45588096
297
Dulaglutide Approved, Investigational 923950-08-7
298
Parathyroid hormone Approved, Investigational 9002-64-6
299
Midazolam Approved, Illicit 59467-70-8 4192
300
Digoxin Approved 20830-75-5 3062 2724385 30322
301
Rituximab Approved 174722-31-7
302
Alfacalcidol Approved, Nutraceutical 41294-56-8 5282181
303
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
304
Calcitriol Approved, Nutraceutical 32222-06-3 5280453
305
Racemethionine Approved, Experimental, Investigational, Nutraceutical 59-51-8, 63-68-3, 348-67-4 6137
306
Vitamin A Approved, Nutraceutical, Vet_approved 2052-63-3, 22737-97-9, 22737-96-8, 68-26-8 9904001 9947823 5280382 445354
307
Choline Approved, Nutraceutical 62-49-7 305
308
Bisphenol A Experimental 80-05-7 6623
309
Potassium iodate Experimental 7758-05-6
310
Opipramol Investigational 315-72-0
311
3,3'-diindolylmethane Investigational Early Phase 1 1968-05-4 3071
312 Hydroxycholecalciferols
313 Pancreatin
314 Cellulose, Oxidized
315 Complement System Proteins
316 Acidophilus
317 Bifidobacterium
318 Citrate
319 Antithyroid Agents
320 Taxane 108169
321 BB 1101
322 Cholinesterase Inhibitors
323 Cholinergic Agents
324 Hemostatics
325 Fibrin fragment D
326 Angiotensin Receptor Antagonists Early Phase 1
327 Sacubitril and valsartan sodium hydrate drug combination Early Phase 1
328 Spirulina
329 Neuromuscular Nondepolarizing Agents
330 Neuromuscular Blocking Agents
331 Lectins
332 Coagulants
333 Agglutinins
334 Nootropic Agents
335 L 647318
336 Dihydromevinolin
337 Parenteral Nutrition Solutions
338 Hematinics
339 Ferrosoferric Oxide
340 Autoantibodies
341 Fibrinolytic Agents
342 Platelet Aggregation Inhibitors
343 Adrenergic alpha-Agonists
344 Adrenergic Agonists
345 Hypnotics and Sedatives
346 Retinol palmitate
347 Adrenergic alpha-Antagonists
348 Adrenergic alpha-1 Receptor Antagonists
349 Pyruvate Early Phase 1
350 Glucagon-Like Peptide 1
351 Antidepressive Agents, Tricyclic
352 Calcium, Dietary
353 Flax
354 Omega 3 Fatty Acid
355 GABA Modulators
356 Anesthetics, Intravenous
357 Anesthetics, General
358 Anti-Anxiety Agents
359
Terephthalic acid 100-21-0 7489
360 Cardiotonic Agents
361 Fluorides
362 Mitogens
363 Cola
364
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 1004)
# Name Status NCT ID Phase Drugs
1 Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism Unknown status NCT02917863 Phase 4 L-Thyroxine (tablet, per os);L-Thyroxine (oral drops, solution)
2 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
3 What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function Unknown status NCT00111735 Phase 4 Thyroxine
4 The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study Unknown status NCT01831869 Phase 4 L-thyroxine
5 Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction Unknown status NCT02512978 Phase 4 Levothyroxine
6 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
7 Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
8 Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General anesthesia---a Randomized Control Double-Blind Clinical Trial Unknown status NCT02613806 Phase 4 Dexmeditomidine;normal saline
9 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
10 Efficacy of Dexmedetomidine for Cough Suppression During Anesthetic Emergence in Patients Undergoing Thyroid Surgery: A Randomized, Double Blinded, Controlled Trial Unknown status NCT03312413 Phase 4 Dexmedetomidine Hydrochloride;Normal Saline
11 Does Sodium Nitroprusside Infusion Affect Thyroidal Function in Patients Undergoing Coronary Artery Bypass Grafting, a Prospective Randomized Clinical Trial. Unknown status NCT00636584 Phase 4 sodium nitroprusside;placebo
12 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
13 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
14 Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) - Subanalysis on Subclinical Hypothyroidism and Depression Completed NCT01853579 Phase 4 Levothyroxine;Placebo
15 Evaluation of Long-term Benefit-risk Profile of Levothyroxine Treatment in Children With Congenital Hypothyroidism: Influence of Initial Levothyroxine Dose on Neurodevelopmental, Growth, Cardiovascular and Skeletal Outcomes Completed NCT05371262 Phase 4 Levothyroxin
16 Assessing Quality of Life Changes Using Calcitonin in Patients With Hypothyroidism on Biochemical Replacement With Levothyroxine Completed NCT03342001 Phase 4 Calcitonin
17 Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study. Completed NCT00531713 Phase 4 Triiodothyronine
18 Impact of Thyroid Hormone Replacement on Cardiac Function: a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism Completed NCT02832960 Phase 4 Levothyroxine;Placebo
19 Impact of Thyroid Hormone Replacement on Progression of Atherosclerosis : a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism. Completed NCT02832934 Phase 4 Levothyroxine;Placebo
20 The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism - a Substudy of TRUST and IEMO Trials Completed NCT04354896 Phase 4 Levothyroxin;Placebo
21 A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
22 Neurocognitive and Metabolic Effects of Mild Hypothyroidism Completed NCT00565864 Phase 4 L-thyroxine (L-T4)
23 Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine Completed NCT01769157 Phase 4 L-carnitine;Placebo
24 Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism Completed NCT02500342 Phase 4 Levothyroxine;Placebo
25 Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial Completed NCT01660126 Phase 4 Levothyroxine;Placebo
26 Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers: A Single-dose, Randomized, Open-label, Crossover Study Completed NCT01536678 Phase 4 Levothyroxine
27 An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors Completed NCT03094416 Phase 4 levothyroxine sodium capsule;Proton pump inhibitor (PPI);Levothyroxine Sodium (LT4) Tablets
28 A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal Completed NCT00001730 Phase 4 Thyrogen
29 A Single-center Interventional Study to Verify Clinical Utility of the Quantitative and the Qualitative POC TSH Test Kits Compared With the Third Generation TSH Test Kit Completed NCT01921452 Phase 4
30 Iodine Intake & Status of Preschoolers Given Micronutrient Powder for 6 Months Completed NCT02280330 Phase 4
31 Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort Completed NCT01647750 Phase 4 Levothyroxine
32 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Completed NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
33 Randomized Controlled Trial of Preoperative Steroids in Autoimmune Thyroid Disease Completed NCT04542278 Phase 4 Prednisone
34 Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results Completed NCT00858104 Phase 4
35 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
36 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
37 A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy. Completed NCT03948191 Phase 4 Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
38 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
39 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
40 Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment Completed NCT02491008 Phase 4 Levothyroxine;Placebo
41 A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism Recruiting NCT05228184 Phase 4 Tirosint®-SOL;Levothyroxine Sodium
42 Effect of Thyroid Replacement Therapy on Thyroid Structure in Patients With Subclinical Hypothyroidism Recruiting NCT04953195 Phase 4 Levothyroxine Sodium Tablets
43 Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused Recruiting NCT05247476 Phase 4 L-T4;L-T4+T3 (thyroid tablet)
44 Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding Recruiting NCT04878614 Phase 4 Levothyroxine Tablet;Levothyroxine Sodium
45 A Prospective, Multicenter Observational Study to Evaluate Thyroid Function of Pediatric Subjects From Birth to 3 Years Exposed to ISOVUE® (Iopamidol Injection) Recruiting NCT03779906 Phase 4 Isovue
46 Effect of Tramadol on Postoperative Sore Throat in Thyroid Surgery Under General Anesthesia With Endotracheal Intubation: A Randomized Controlled Trial Recruiting NCT04991493 Phase 4 Tramadol hydrochloride
47 A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease Recruiting NCT04583735 Phase 4 Placebo
48 Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study) Recruiting NCT04574947 Phase 4 Intravenous lidocaine;Intravenous placebo
49 Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism: a Pilot Randomized, Double-blinded, Placebo-controlled Study Active, not recruiting NCT04288115 Phase 4 Levothyroxine
50 Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism Active, not recruiting NCT01848171 Phase 4 L-thyroxine

Search NIH Clinical Center for Hypothyroidism

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Kelp preparation

Cochrane evidence based reviews: hypothyroidism

Genetic Tests for Hypothyroidism

Genetic tests related to Hypothyroidism:

# Genetic test Affiliating Genes
1 Hypothyroidism 28

Anatomical Context for Hypothyroidism

Organs/tissues related to Hypothyroidism:

MalaCards : Thyroid, Heart, Lymph Node, Eye, Pituitary, Brain, Breast

Publications for Hypothyroidism

Articles related to Hypothyroidism:

(show top 50) (show all 43096)
# Title Authors PMID Year
1
Using the Baidu index to understand Chinese interest in thyroid related diseases. 62 41
36229549 2022
2
Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients. 62 41
36229814 2022
3
New insights into thyroid dysfunction in patients with inactivating parathyroid hormone/parathyroid hormone-related protein signalling disorder (the hormonal and ultrasound aspects): One-centre preliminary results. 62 41
36213284 2022
4
Analysis of thyroid involvement in children and adult Langerhans cell histiocytosis: An underestimated endocrine manifestation. 62 41
36246871 2022
5
Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study. 62 41
36246884 2022
6
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
7
Association of thyroid function test abnormalities with preeclampsia: a systematic review and meta-analysis. 41
36163002 2022
8
Genetics and phenomics of hypothyroidism and thyroid dys- and agenesis due to PAX8 and TTF1 mutations. 53 62
20302910 2010
9
Genetics and phenomics of hypothyroidism and goiter due to thyroglobulin mutations. 53 62
20093166 2010
10
Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. 53 62
20332126 2010
11
Runx2 deficiency in mice causes decreased thyroglobulin expression and hypothyroidism. 53 62
20375239 2010
12
Congenital hypothyroidism in a kitten resulting in decreased IGF-I concentration and abnormal liver function tests. 53 62
20223692 2010
13
Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. 53 62
20153806 2010
14
Genetics and phenomics of hypothyroidism and goiter due to NIS mutations. 53 62
20153805 2010
15
Dual oxidase, hydrogen peroxide and thyroid diseases. 53 62
20407074 2010
16
Four patients with hypothyroid Graves' disease. 53 62
20421660 2010
17
Biallelic p.R2223H mutation in the thyroglobulin gene causes thyroglobulin retention and severe hypothyroidism with subsequent development of thyroid carcinoma. 53 62
20089614 2010
18
Turner syndrome and schizophrenia: a further hint for the role of the X-chromosome in the pathogenesis of schizophrenic disorders. 53 62
20218787 2010
19
Molecular analysis of congenital goitres with hypothyroidism caused by defective thyroglobulin synthesis. Identification of a novel c.7006C>T [p.R2317X] mutation and expression of minigenes containing nonsense mutations in exon 7. 53 62
19438905 2010
20
Environmental pollutants and the thyroid. 53 62
19942155 2009
21
Broad clinical involvement in a family affected by the fragile X premutation. 53 62
19996900 2009
22
Diagnosis and discrimination of autoimmune Graves' disease and Hashimoto's disease using thyroid-stimulating hormone receptor-containing recombinant proteoliposomes. 53 62
19914592 2009
23
Panhypopituitarism due to metastases to the hypothalamus and the pituitary resulting from primary breast cancer: a case report and review of the literature. 53 62
19933072 2009
24
Thyrotropin-stimulating hormone receptor gene analysis in pediatric patients with non-autoimmune subclinical hypothyroidism. 53 62
19820021 2009
25
Congenital leptin deficiency and thyroid function. 53 62
19889232 2009
26
GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. 53 62
19684055 2009
27
[Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease]. 53 62
20030174 2009
28
Radioiodine ablation: when and how. 53 62
19910900 2009
29
More hypothyroidism and less hyperthyroidism with sufficient iodine nutrition compared to mild iodine deficiency--a comparative population-based study of older people. 53 62
19762181 2009
30
Subclinical hypothyroidism and autoimmune thyroiditis in pregnancy--a study in south Indian subjects. 53 62
20329425 2009
31
Final diagnosis in children with subclinical hypothyroidism and mutation analysis of the thyroid peroxidase gene (TPO). 53 62
19960894 2009
32
The p.A2215D thyroglobulin gene mutation leads to deficient synthesis and secretion of the mutated protein and congenital hypothyroidism with wide phenotype variation. 53 62
19509106 2009
33
Ovarian hyper-stimulation syndrome after spontaneous conception. 53 62
19499413 2009
34
Subclinical hypothyroidism in children and adolescents: a wide range of clinical, biochemical, and genetic factors involved. 53 62
19417038 2009
35
[Sarcoidosis associated with hypothyroidism due to thyrotropin-receptor blocking antibodies]. 53 62
18930567 2009
36
[An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value]. 53 62
19504446 2009
37
Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction. 53 62
19111490 2009
38
Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. 53 62
19293265 2009
39
Effects of thyroxine replacement on serum creatinine and cystatin C in patients with primary and central hypothyroidism. 53 62
19529992 2009
40
TSH receptor - autoantibody interactions. 53 62
19530271 2009
41
Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition. 53 62
19415994 2009
42
Persistence of goitre in children post-salt iodization in Islamic Republic of Iran: autoimmune status. 53 62
19731774 2009
43
[Sodium-iodine symporter in thyroid, normal and cancer tissues and its relation to nuclear medicine and to gene cloning treatment]. 53 62
19675882 2009
44
Evolution of sonographic appearance of the thyroid gland in children with Hashimoto's thyroiditis. 53 62
19554808 2009
45
Mainly the younger hypothyroid patients are referred to hospital--evidence for referral bias. 53 62
18945587 2009
46
Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. 53 62
19175874 2009
47
Influence of iodide excess and interferon-gamma on human primary thyroid cell proliferation, thyroglobulin secretion, and intracellular adhesion molecule-1 and human leukocyte antigen-DR expression. 53 62
19265500 2009
48
Cardiac troponin T is not increased in patients with hypothyroidism. 53 62
19356187 2009
49
An inactivating mutation within the first extracellular loop of the thyrotropin receptor impedes normal posttranslational maturation of the extracellular domain. 53 62
18927215 2009
50
Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. 53 62
19208310 2009

Variations for Hypothyroidism

ClinVar genetic disease variations for Hypothyroidism:

5 (show all 15)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHD7 NM_017780.4(CHD7):c.6892C>T (p.Gln2298Ter) SNV Pathogenic
374090 rs1057518891 GRCh37: 8:61767038-61767038
GRCh38: 8:60854479-60854479
2 STAT1 NM_007315.4(STAT1):c.1154C>T (p.Thr385Met) SNV Pathogenic
Pathogenic
144006 rs587777630 GRCh37: 2:191851647-191851647
GRCh38: 2:190986921-190986921
3 GNB1 NM_002074.5(GNB1):c.239T>C (p.Ile80Thr) SNV Pathogenic
208722 rs752746786 GRCh37: 1:1737942-1737942
GRCh38: 1:1806503-1806503
4 RET NM_020975.6(RET):c.2753T>C (p.Met918Thr) SNV Pathogenic
13919 rs74799832 GRCh37: 10:43617416-43617416
GRCh38: 10:43121968-43121968
5 POGZ NM_015100.4(POGZ):c.402_409dup (p.His137fs) DUP Likely Pathogenic
373957 rs1057518799 GRCh37: 1:151403191-151403192
GRCh38: 1:151430715-151430716
6 ADNP NM_001282531.3(ADNP):c.2188C>T (p.Arg730Ter) SNV Likely Pathogenic
279598 rs886041116 GRCh37: 20:49509063-49509063
GRCh38: 20:50892526-50892526
7 TG NM_003235.5(TG):c.5804del (p.Asn1935fs) DEL Likely Pathogenic
689597 rs1587618417 GRCh37: 8:133980155-133980155
GRCh38: 8:132967910-132967910
8 SLC33A1 NM_004733.4(SLC33A1):c.963+1G>A SNV Likely Pathogenic
812763 rs1266904735 GRCh37: 3:155560220-155560220
GRCh38: 3:155842431-155842431
9 SLC26A4 NM_000441.2(SLC26A4):c.1301C>A (p.Ala434Asp) SNV Uncertain Significance
591607 rs1035397261 GRCh37: 7:107334885-107334885
GRCh38: 7:107694440-107694440
10 overlap with 3 genes GRCh37/hg19 6q25.3(chr6:156772218-157870875)x3 CN GAIN Uncertain Significance
523303 GRCh37: 6:156772218-157870875
GRCh38:
11 HUWE1 NM_031407.7(HUWE1):c.6485G>C (p.Arg2162Pro) SNV Uncertain Significance
523539 rs1556948950 GRCh37: X:53596615-53596615
GRCh38: X:53569655-53569655
12 TSHR NM_000369.5(TSHR):c.202C>T (p.Pro68Ser) SNV Uncertain Significance
437071 rs142063461 GRCh37: 14:81528523-81528523
GRCh38: 14:81062179-81062179
13 PAX8 NM_003466.4(PAX8):c.1011del (p.Val339fs) DEL Uncertain Significance
598954 rs1558700308 GRCh37: 2:113993047-113993047
GRCh38: 2:113235470-113235470
14 CR1 NM_000651.6(CR1):c.6283C>A (p.His2095Asn) SNV Uncertain Significance
812547 rs1571590802 GRCh37: 1:207783021-207783021
GRCh38: 1:207609676-207609676
15 SCNN1A NM_001038.6(SCNN1A):c.1427G>A (p.Arg476Gln) SNV Uncertain Significance
598965 rs72657556 GRCh37: 12:6458505-6458505
GRCh38: 12:6349339-6349339

Expression for Hypothyroidism

Search GEO for disease gene expression data for Hypothyroidism.

Pathways for Hypothyroidism

GO Terms for Hypothyroidism

Biological processes related to Hypothyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 retina development in camera-type eye GO:0060041 9.93 RET GNB1 CHD7
2 positive regulation of multicellular organism growth GO:0040018 9.8 TSHR DIO3 CHD7
3 thyroid hormone generation GO:0006590 9.8 TPO TG SLC5A5
4 cellular response to gonadotropin stimulus GO:0071371 9.73 SLC5A5 PAX8
5 hormone biosynthetic process GO:0042446 9.73 DIO3 TG TPO
6 thyroid-stimulating hormone signaling pathway GO:0038194 9.67 TSHR PAX8
7 thyroid gland development GO:0030878 9.56 TG PAX8 NKX2-5 NKX2-1
8 thyroid hormone metabolic process GO:0042403 9.55 TG IYD DIO3
9 iodide transport GO:0015705 9.1 TG SLC5A5 SLC26A4

Molecular functions related to Hypothyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.63 STAT1 PAX8 NKX2-5 NKX2-1 GLIS3
2 iodide transmembrane transporter activity GO:0015111 9.26 SLC5A5 SLC26A4
3 thyroid-stimulating hormone receptor activity GO:0004996 8.92 TSHR PAX8

Sources for Hypothyroidism

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....